Faeth Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 3, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 3, 2026

FTH$22.05+10.7%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Faeth Therapeutics, Inc.
Date:	November 3, 2026	By:	/s/ Anand Parikh
			Anand Parikh
			Principal Executive Officer
Date:	November 3, 2026	By:	/s/ Brian Stephenson
			Brian Stephenson
			Principal Financial Officer
Date:	November 3, 2026	By:	/s/ Josiah Craver
			Josiah Craver
			Senior Vice President of Finance
			Principal Accounting Officer

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.